Idlir Liko, DPhil (he/him/his)

OMass Therapeutics, England, United Kingdom

Idlir Liko is the Technology Director and founder of OMass Therapeutics. He received a Master’s Degree from ETH Zurich in 2012 and DPhil from the University of Oxford in 2015, supervised by Prof. Dame Carol Robinson where he focused on the effect ligands and PTMs have on structure and stability of membrane proteins. His work was been featured in many high-impact publications. He has a wealth of experience in structural MS working in close collaboration with biotech and pharmaceutical companies. In 2016, he co-founded OMass Therapeutics and has played a key role in transferring the technology from academia to industry.

Disclosure information not submitted.

Presentation(s):

• High-throughput Label-free Screening Technologies

  Tuesday, February 6, 2024
  3:00 PM – 5:00 PM EST

• High Throughput Screening by Native Mass Spectrometry - Identifying binders, with the desired functionality, to membrane protein and intricate targets.

  Tuesday, February 6, 2024
  3:30 PM – 4:00 PM EST